A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04691804)

🧪 Interventions in This Study

• Fuzuloparib , Abiraterone acetate and Prednisone (DRUG)
• Fuzuloparib Placebo， Abiraterone acetate and Prednisone (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (147 Sites)

Showing the first 25 of 147 sites.

• Alaska Oncology and Hematology LLC — Anchorage, Alaska
• Urological Associates of Southern Arizona PC — Tucson, Arizona
• Desert Hematology Oncology Medical Group Inc — Rancho Mirage, California
• San Bernardino Urological Associates Medical Group — San Bernardino, California
• UF College of Medicine - Jacksonville — Jacksonville, Florida
• Hematology Oncology Clinic — Baton Rouge, Louisiana
• VA Maryland Health Care System — Baltimore, Maryland
• Johns Hopkins — Baltimore, Maryland
• Henry Ford Health System — Detroit, Michigan
• GU Research Network LLC — Omaha, Nebraska
• John Theurer Cancer Center — Hackensack, New Jersey
• Weill Cornell Medicine — New York, New York
• Messino Cancer Centers — Asheville, North Carolina
• Gabrail Cancer Center Research — Canton, Ohio
• Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
• Tennessee Oncology — Chattanooga, Tennessee
• Center for Onology and Blood Disorders — Houston, Texas
• Bendigo Health — Bendigo,
• Concord Repatriation General Hospital — Concord,
• St Vincents Hospital Melbourne — Fitzroy,
• Gosford Hospital — Gosford,
• Ashford Cancer Centre Research — Kurralta Park,
• The Alfred Hospital — Melbourne,
• Western Health — St Albans,
• Macquarie University — Sydney,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

• Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer — Oklahoma City, Oklahoma
• PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA — Kelowna, British Columbia
• Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function — New York, New York
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T — Tuscon, Arizona
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors — Gilbert, Arizona

Explore by condition: All Metastatic Castration-Resistant Prostate Cancer (mCRPC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.